Immunomodulation of FOXP3+ regulatory T cells by the aromatase inhibitor letrozole in breast cancer patients.

Immunomodulation of FOXP3+ regulatory T cells by the aromatase inhibitor letrozole in breast cancer patients.

PURPOSE: We have shown previously that tumor infiltration by FOXP3+ regulatory T cells (Treg) is associated with increased relapse and shorter survival of patients with both in situ and invasive breast cancer. Because estrogen regulates Treg numbers in mice and promotes the proliferation of human T...

Volledige beschrijving

Bibliografische gegevens
Hoofdauteurs:	Generali, D, Bates, G, Berruti, A, Brizzi, M, Campo, L, Bonardi, S, Bersiga, A, Allevi, G, Milani, M, Aguggini, S, Dogliotti, L, Banham, A, Harris, A, Bottini, A, Fox, S
Formaat:	Journal article
Taal:	English
Gepubliceerd in:	2009

Gelijkaardige items

Down-regulation of phosphatidylinositol 3'-kinase/AKT/molecular target of rapamycin metabolic pathway by primary letrozole-based therapy in human breast cancer.
door: Generali, D, et al.
Gepubliceerd in: (2008)

Effect of primary letrozole (LET) vs letrozole plus metronomic cyclophosphamide (LET-CYC) on Treg infiltration in ER plus ve breast cancer.
door: Fox, S, et al.
Gepubliceerd in: (2006)

The prolyl hydroxylase enzymes are positively associated with hypoxia-inducible factor-1α and vascular endothelial growth factor in human breast cancer and alter in response to primary systemic treatment with epirubicin and tamoxifen
door: Fox, S, et al.
Gepubliceerd in: (2011)

The prolyl hydroxylase enzymes are positively associated with hypoxia-inducible factor-1α and vascular endothelial growth factor in human breast cancer and alter in response to primary systemic treatment with epirubicin and tamoxifen.
door: Fox, S, et al.
Gepubliceerd in: (2011)

Anti-angiogenic effect of tamoxifen combined with epirubicin in breast cancer patients.
door: Mele, T, et al.
Gepubliceerd in: (2010)

Anti-angiogenic effect of tamoxifen combined with epirubicin in breast cancer patients
door: Mele, T, et al.
Gepubliceerd in: (2010)

Phosphorylated ERalpha, HIF-1alpha, and MAPK signaling as predictors of primary endocrine treatment response and resistance in patients with breast cancer.
door: Generali, D, et al.
Gepubliceerd in: (2009)

Regulation of hepatocyte growth factor activator inhibitor 2 by hypoxia in breast cancer
door: Generali, D, et al.
Gepubliceerd in: (2007)

Regulation of hepatocyte growth factor activator inhibitor 2 by hypoxia in breast cancer.
door: Generali, D, et al.
Gepubliceerd in: (2007)

Factor analysis of predictive markers of response and resistance to primary chemo-endocrine treatment in elderly breast cancer (BC) patients
door: Generali, D, et al.
Gepubliceerd in: (2006)

Principal factor analysis of predictive markers of response and resistance to primary chemo-endocrine treatment in elderly breast cancer (BC) patients.
door: Generali, D, et al.
Gepubliceerd in: (2006)

Increased pathological complete response rate after a long-term neoadjuvant letrozole treatment in postmenopausal oestrogen and/or progesterone receptor-positive breast cancer
door: Allevi, G, et al.
Gepubliceerd in: (2013)

Increased pathological complete response rate after a long-term neoadjuvant letrozole treatment in postmenopausal oestrogen and/or progesterone receptor-positive breast cancer.
door: Allevi, G, et al.
Gepubliceerd in: (2013)

Factor analysis of predictive markers of response and resistance to primary chemo-endocrine treatment in elderly breast cancer (BC) patients
door: Generali, D, et al.
Gepubliceerd in: (2006)

DOWN-REGULATION OF HYPOXIA INDUCIBILE FACTOR-1 alpha (HIF-1 alpha) EXPRESSION, THROUGH mTOR PATHWAY, BY LETROZOLE (FEMARA (R)) IN ER plus ve BREAST CANCER PATIENTS: CLINICAL IMPLICATIONS
door: Foroni, C, et al.
Gepubliceerd in: (2009)

Molecular oncology and the neoadjuvant setting: the perfect blend for treatment personalization and clinical trial design.
door: Generali, D, et al.
Gepubliceerd in: (2011)

Changes of bone turnover markers and serum PTH after night or morning administration of zoledronic acid in breast cancer patients with bone metastases.
door: Generali, D, et al.
Gepubliceerd in: (2008)

ΔKi67 proliferation index as independent predictive and prognostic factor of outcome in luminal breast cancer: data from neoadjuvant letrozole-based treatment
door: A Ianza, et al.
Gepubliceerd in: (2020-06-01)

Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with T2 to T4, N0 and N1 breast cancer
door: Andreis, D, et al.
Gepubliceerd in: (2016)

Effect of Letrozole Administration as a Selective Aromatase Inhibitor on Male Rat's Reproductive Performance
door: A Hmood Jassim, et al.
Gepubliceerd in: (2022-02-01)

Synergistic activity of letrozole and sorafenib on breast cancer cells.
door: Bonelli, M, et al.
Gepubliceerd in: (2010)

Estrogen/androgen balance in men with hyperestrogenism normalized by using letrozole of the aromatase inhibitor drug class
door: Z. Sh. Pavlova, et al.
Gepubliceerd in: (2022-03-01)

Interaction of Zinc Chloride with an Aromatase Inhibitor (Letrozole) on Anxiety in Adult Male Rats
door: Sahar Charghan, et al.
Gepubliceerd in: (2016-12-01)

#120 : Effect of Aromatase Inhibitor, Letrozole on Semen Parameters in Eugonadotropic Hypoandrogenic Men with Oligozoospermia
door: Israt Jahan
Gepubliceerd in: (2023-12-01)

Effect of Aromatase Inhibitor Letrozole on the Placenta of Adult Albino Rats: A Histopathological, Immunohistochemical, and Biochemical Study
door: Mohamed Ali Alabiad, et al.
Gepubliceerd in: (2024-01-01)

Expression of the forkhead transcription factor FOXP1 is associated with that of estrogen receptor-beta in primary invasive breast carcinomas.
door: Bates, G, et al.
Gepubliceerd in: (2008)

Letrozole, an aromatase inhibitor, improves seminal parameters and hormonal profile in aged endangered Markhoz bucks
door: Ako Rezaei, et al.
Gepubliceerd in: (2022-11-01)

The aromatase inhibitor letrozole enhances the effect of doxorubicin and docetaxel in an MCF7 cell line model
door: Mary O’Neill, et al.
Gepubliceerd in: (2012-12-01)

Therapeutic targeting of FOXP3-positive regulatory T cells using a FOXP3 peptide vaccine WO2008081581.
door: Banham, A, et al.
Gepubliceerd in: (2009)

Design of Novel Letrozole Analogues Targeting Aromatase for Breast Cancer: Molecular Docking, Molecular Dynamics, and Theoretical Studies on Gold Nanoparticles
door: Alaa Edris, et al.
Gepubliceerd in: (2023-04-01)

The FOXP3 transcription factor as a regulatory T-cell marker
door: Banham, A
Gepubliceerd in: (2008)

Interaction of letrozole and its degradation products with aromatase: chemometric assessment of kinetics and structure-based binding validation
door: Michele De Luca, et al.
Gepubliceerd in: (2022-12-01)

Effectiveness of the aromatase (P450 Arom) inhibitors Letrozole and Exemestane for masculinization of red tilapia (Oreochromis spp.)
door: John J Betancur López, et al.
Gepubliceerd in: (2014-03-01)

High numbers of tumor-infiltrating FOXP3-positive regulatory T cells are associated with improved overall survival in follicular lymphoma.
door: Carreras, J, et al.
Gepubliceerd in: (2006)

Monoclonal antibodies raised to the human FOXP3 protein can be used effectively for detecting Foxp3(+) T cells in other mammalian species.
door: Banham, A, et al.
Gepubliceerd in: (2009)

The presence of tumor-infiltrating FOXP3+ lymphocytes correlates with intratumoral angiogenesis in endometrial cancer.
door: Giatromanolaki, A, et al.
Gepubliceerd in: (2008)

Expression of the forkhead box transcription factor FOXP1 is associated with oestrogen receptor alpha, oestrogen receptor beta and improved survival in familial breast cancers.
door: Rayoo, M, et al.
Gepubliceerd in: (2009)

FOXP3+ regulatory T cells as biomarkers in human malignancies.
door: Bignone, P, et al.
Gepubliceerd in: (2008)

Combined aromatase, CDK4/6 and PI3K blockade using letrozole/abemaciclib/LY3023414 in endometrial cancer
door: Panagiotis A. Konstantinopoulos, et al.
Gepubliceerd in: (2024-04-01)

FOXP1: a potential therapeutic target in cancer.
door: Koon, H, et al.
Gepubliceerd in: (2007)